Drug Evaluation Committee Guidance on "Provision of Medical and Scientific Information" by the Medical Affairs Section
Medical Affairs Subcommittee
December 2022
The MA Subcommittee's Continuing Task Force 5 has been discussing how the Medical Affairs Division should provide medical and scientific information from 2020, and has now published "A Guide to the Provision of Medical and Scientific Information by the Medical Affairs Division" as a deliverable of the Drug Evaluation Committee. The "Guideline for the Provision of Medical and Scientific Information by the Medical Affairs Division" is a product of the Pharmaceutical Evaluation Committee.
We hope that this "Guide to the Provision of Medical and Scientific Information by the Medical Affairs Section" will be helpful to the medical activities of the member companies of the Drug Evaluation Committee.
Japan Pharmaceutical Manufacturers Association, Committee on Drug Evaluation
MA Subcommittee 2022 Ongoing Task Force 5
Deliverables of the Drug Evaluation Committee Return to list of all deliverables